Dyne Therapeutics Inc [DYN] stock is trading at $9.21, up 0.44%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DYN shares have gain 11.23% over the last week, with a monthly amount drifted -10.76%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on June 24, 2025, when Bernstein initiated its Mkt Perform rating and assigned the stock a price target of $13. Evercore ISI started tracking the stock assigning a Outperform rating and suggested a price target of $46 on May 29, 2025. BMO Capital Markets initiated its recommendation with a Outperform and recommended $50 as its price target on March 12, 2025. Scotiabank started tracking with a Sector Outperform rating for this stock on March 07, 2025, and assigned it a price target of $50. In a note dated December 13, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $46 on this stock.
Dyne Therapeutics Inc [DYN] stock has fluctuated between $6.36 and $47.45 over the past year. Currently, Wall Street analysts expect the stock to reach $42.67 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $9.21 at the most recent close of the market. An investor can expect a potential return of 363.3% based on the average DYN price forecast.
Analyzing the DYN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.53 and Total Capital is -0.58. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.10 points at the first support level, and at 8.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.35, and for the 2nd resistance point, it is at 9.49.
Ratios To Look Out For
For context, Dyne Therapeutics Inc’s Current Ratio is 20.35. In addition, the Quick Ratio stands at 20.35 and the Cash Ratio stands at 13.94.
Transactions by insiders
Recent insider trading involved Cox John, CEO & President, that happened on Jul 14 ’25 when 100000.0 shares were purchased. Officer, Scalzo Richard William completed a deal on Jun 11 ’25 to buy 1330.0 shares. Meanwhile, Officer Beskrovnaya Oxana bought 2132.0 shares on Jun 11 ’25.
